Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLUESTAR-Endometrial01
CTR20254547Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of puxitatug samrotecan in endometrial cancer (EC), sponsored by AstraZeneca. Started Mar 2026; status: active.
02
Drugs
puxitatug samrotecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20254547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254547.